Literature DB >> 3882691

Primary structure of a glycosylated DNA-binding domain in human plasma fibronectin.

H Pande, J Calaycay, D Hawke, C M Ben-Avram, J E Shively.   

Abstract

The complete amino acid sequence of a DNA-binding domain isolated from human plasma fibronectin after limited trypsin digestion has been obtained. It contains 132 amino acids and one biantennary glycosyl unit at residue 104, for an estimated Mr of 16,931. The fragment can be purified by a two-step procedure consisting of DNA-affinity chromatography and reverse-phase high performance liquid chromatography. It can also be purified by heparin-affinity chromatography. The domain is unusual in its susceptibility to tryptic-like cleavages even by neutral or aromatic residue-specific proteases. It has no cysteine residues and is predicted to favor a beta-sheet structure by Chou and Fasman analysis. Based on this analysis we have proposed a model which exhibits a clustering of aromatic and basic residues, consistent with similar involvement of basic and aromatic residues in other DNA-binding proteins. The net charge of the domain at neutral pH (+1, without sialic acid) argues against a nonspecific charge interaction with polyanionic macromolecules such as DNA and heparin. Internal sequence repeats occur at intervals of 30, 60, and 90 residues, thus suggesting a maximum size for a repetitive building block which gave rise to this domain.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882691

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Interaction of heparin with fibronectin and isolated fibronectin domains.

Authors:  K C Ingham; S A Brew; D H Atha
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

2.  Primary structure of human plasma fibronectin. Characterization of a 38 kDa domain containing the C-terminal heparin-binding site (Hep III site) and a region of molecular heterogeneity.

Authors:  A Garcia-Pardo; A Rostagno; B Frangione
Journal:  Biochem J       Date:  1987-02-01       Impact factor: 3.857

Review 3.  Neutrophil extracellular trap (NET) impact on deep vein thrombosis.

Authors:  Tobias A Fuchs; Alexander Brill; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-31       Impact factor: 8.311

4.  Extracellular DNA traps promote thrombosis.

Authors:  Tobias A Fuchs; Alexander Brill; Daniel Duerschmied; Daphne Schatzberg; Marc Monestier; Daniel D Myers; Shirley K Wrobleski; Thomas W Wakefield; John H Hartwig; Denisa D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-23       Impact factor: 11.205

5.  Models of fibronectin.

Authors:  M Rocco; E Infusini; M G Daga; L Gogioso; C Cuniberti
Journal:  EMBO J       Date:  1987-08       Impact factor: 11.598

6.  Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells.

Authors:  L Borsi; B Carnemolla; P Castellani; C Rosellini; D Vecchio; G Allemanni; S E Chang; J Taylor-Papadimitriou; H Pande; L Zardi
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

7.  Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells.

Authors:  Marcello Monti; Francesca Iommelli; Viviana De Rosa; Maria Vincenza Carriero; Roberta Miceli; Rosa Camerlingo; Giovanni Di Minno; Silvana Del Vecchio
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

8.  Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19.

Authors:  Malgorzata Wygrecka; Anna Birnhuber; Benjamin Seeliger; Laura Michalick; Oleg Pak; Astrid-Solveig Schultz; Fabian Schramm; Martin Zacharias; Gregor Gorkiewicz; Sascha David; Tobias Welte; Julius J Schmidt; Norbert Weissmann; Ralph T Schermuly; Guillermo Barreto; Liliana Schaefer; Philipp Markart; Markus C Brack; Stefan Hippenstiel; Florian Kurth; Leif E Sander; Martin Witzenrath; Wolfgang M Kuebler; Grazyna Kwapiszewska; Klaus T Preissner
Journal:  Blood Adv       Date:  2022-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.